Jordi Remon/X
Jan 26, 2025, 12:01
Jordi Remon: Teliso-V and osimertinib – the METamorphosis of EGFR-mutant lung cancer?
Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared on X:
“TelisoV+Osi potential ttx in MET overex meta EGFRm NSCLC with osi resist disease.
Hw:
Other ADCs with activity
Not easy tissue Bx at PD for testing MET
New 1stL options may decrease MET expression at PD?
Brain activity.”
Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer? – Annals of Oncology
Authors: S.P.L. Saw
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 06:51
Feb 24, 2025, 23:27
Feb 24, 2025, 15:25
Feb 24, 2025, 14:55
Feb 24, 2025, 14:51
Feb 24, 2025, 14:45
Feb 24, 2025, 14:22
Feb 24, 2025, 14:08
Feb 24, 2025, 14:00